liver disease

GSK scratches itch for phase 3 win, hitting goal in liver disease trial to open up untapped market
Fierce Biotech
Tue, 11/19/24 - 11:18 am
GSK
linerixibat
liver disease
clinical trials
FDA declines full approval for Intercept's liver disease drug
Pharma Live
Tue, 11/12/24 - 11:10 am
Intercept Pharma
Ocaliva
FDA
primary biliary cholangitis
liver disease
Galecto buys leukemia drug from Bridge Medicines, drops bone cancer asset in strategic pivot
Fierce Biotech
Mon, 10/7/24 - 11:36 am
Galecto
oncology
liver disease
leukemia
Bridge Medicine
US FDA staff questions confirmatory trial data for Intercept's liver disease drug
Reuters
Wed, 09/11/24 - 11:51 am
FDA
Intercept Pharma
Ocaliva
clinical trials
primary biliary cholangitis
liver disease
FDA approves Gilead's seladelpar for primary biliary cholangitis
First Word Pharma
Wed, 08/14/24 - 10:35 pm
Gilead Sciences
seladelpar
Livdelzi
liver disease
primary biliary cholangitis
On doorstep of FDA decision, Gilead pays J&J $320M to exit licensing deal for seladelpar
Fierce Biotech
Fri, 08/9/24 - 11:23 am
Gilead Sciences
seladelpar
liver disease
JNJ
Calliditas' liver disease trial hits primary endpoint after sweeping changes to design
Fierce Biotech
Fri, 07/26/24 - 11:08 am
Calliditas
liver disease
primary biliary cholangitis
clinical trials
setanaxib
GSK signs AI pact with Ochre to pinpoint source of liver diseases
Fierce Biotech
Wed, 06/12/24 - 11:53 am
GSK
Ochre Bio
liver disease
artificial intelligence
computational biology
Gilead's new liver disease med continues to deliver the goods ahead of FDA verdict
Fierce Biotech
Mon, 05/20/24 - 10:59 am
Gilead Sciences
CymaBay Therapeutics
seladelpar
liver disease
Drugs Like Ozempic And Mounjaro Could Treat Other Conditions—Here’s What Scientists Are Looking At
Forbes
Thu, 04/18/24 - 10:25 pm
Novo Nordisk
Eli Lilly
Ozempic
Wegovy
Zepbound
Mounjaro
anxiety
addiction
heart disease
liver disease
FDA approves expanded use of Mirum's liver disease drug
Reuters
Wed, 03/13/24 - 10:40 pm
Mirum Pharmaceuticals
FDA
liver disease
PFIC
Gilead pays $4.3B for CymaBay, the biotech that never gave up on liver disease med
Fierce Biotech
Mon, 02/12/24 - 11:53 am
Gilead Sciences
CymaBay Therapeutics
M&A
liver disease
seladelpar
primary biliary cholangitis
Obesity drugs’ next tests, and rising threats: 3 chronic disease stories to watch
Stat
Thu, 12/21/23 - 09:52 am
obesity
climate change
Wegovy
Zepbound
Novo Nordisk
Eli Lilly
liver disease
Ipsen, eyeing approval, reveals mixed liver disease data on challenger to Intercept and CymaBay
Fierce Biotech
Tue, 11/14/23 - 09:20 am
Ipsen
Genfit
elafibranor
liver disease
Intercept Pharma
CymaBay Therapeutics
3 Massive New Markets Could Await Ozempic, And They Might Make Novo Nordisk Investors Richer
Motley Fool
Thu, 08/24/23 - 09:50 pm
Novo Nordisk
Ozempic
diabetes
weight loss
liver disease
addiction
cardiovascular disease
Genethon’s Gene Therapy for Rare Liver Disease Shows Promising Early-Stage Results
BioSpace
Fri, 08/18/23 - 11:37 am
Genethon
gene therapy
Crigler-Najjar Syndrome
liver disease
clinical trials
Ipsen and Genfit to file for EMA and FDA approval for elafibranor
Clinical Trials Arena
Fri, 06/30/23 - 10:12 am
Ipsen
Genfit
EMA
FDA
elafibranor
liver disease
primary biliary cholangitis
After Albireo buyout, Ipsen's Bylvay picks up new FDA-approved use
Fierce Pharma
Wed, 06/14/23 - 10:22 am
Ipsen
Bylvay
Albireo Pharma
M&A
FDA
liver disease
Mallinckrodt secures FDA approval — but not without warning
Endpoints
Thu, 09/15/22 - 11:18 pm
Mallinckrodt
FDA
terlipressin
Terlivaz
liver disease
hepatorenal syndrome
Vertex, Verve team up to develop a gene editing drug for liver disease
Biopharma Dive
Wed, 07/20/22 - 11:24 pm
Vertex Pharma
Verve Therapeutics
liver disease

Pages